Research progress on drugs targeting the TGF-beta signaling pathway in fibrotic diseases.

Article Details

Citation
Copy to clipboard

Shi N, Wang Z, Zhu H, Liu W, Zhao M, Jiang X, Zhao J, Ren C, Zhang Y, Luo L

Research progress on drugs targeting the TGF-beta signaling pathway in fibrotic diseases.

Immunol Res. 2022 Jun;70(3):276-288. doi: 10.1007/s12026-022-09267-y. Epub 2022 Feb 11.

PubMed ID
35147920 [ View in PubMed
]
Abstract

Tissue fibrosis is a key factor leading to disability and death worldwide; however, thus far, there are no approved treatments for fibrosis. Transforming growth factor (TGF)-beta is a major pro-fibrotic cytokine, which is expected to become a target in the treatment of fibrosis; however, since TGF-beta has a wide range of biological functions involving a variety of biological processes in the body, a slight change in TGF-beta may have a systematic effect. Indiscriminate inhibition of TGF-beta can lead to adverse reactions, which can affect the efficacy of treatment. Therefore, it has become very important to explore how both the TGF-beta signaling pathway is inhibited and the safe and efficient TGF-beta small molecule inhibitors or neutralizing antibodies are designed in the treatment of fibrotic diseases. In this review, we mainly discuss the key role of the TGF-beta signaling pathway in fibrotic diseases, as well as the development of fibrotic drugs in recent years, and explore potential targets in the treatment of fibrotic diseases in order to guide subsequent drug development.

DrugBank Data that Cites this Article

Drugs